

CURRICULUM VITAE



PERSOENLICHE DATEN

Name: Olav Lapaire-Mayer
Akad. Grad: Prof. Dr. med.
Derzeit. Funktion: Leitender Arzt / stv. Chefarzt
Geburtshilfe und Schwangerschaftsmedizin
Leiter Ultraschallabteilung
Klinikadresse: Frauenklinik Universitätsspital Basel
Spitalstrasse 21
CH-4031 Basel
Telefon: + 41 61 265 90 17
E-Mail: olapaire@usb.ch
Private Adresse: Neubadrain 92
CH-4102 Binningen
Tel: +41 61 641 77 12
Geburtsdatum: April 11, 1970
Geburtsort: Palo Alto, California, USA
Heimatort: Schaffhausen
Zivilstand: verheiratet mit Denise Lapaire, 1 Sohn (Eric)
Hobbies: Familie, klassische Literatur, Antiquitäten, Garten

AUSBILDUNG

1990 Matura, Typus B
1990-1996 Medizin Studium, Universität Basel
1996 Staatsexamen, Universität Basel
1997 Promotion, Universität Basel
1998 Chirurgisches Basisexamen, FMH, Bern
2004 Zertifikat der Fetal Medicine Foundation for Nuchal translucency measurement in the first trimester
10/2004 Facharzt-Examen Gynäkologie und Geburtshilfe FMH
01-12/2005 Post-doctoral fellowship am Tufts-New England Medical Center, Boston, USA

11/2005	Zertifikat der Fetal Medicine Foundation for <i>Theoretical course for the Certificate of Competence in Ultrasound Examination at 11-14 weeks</i>
10/2008	Habilitation im Fach Gynäkologie und Geburtshilfe Antrittsvorlesung: <i>Alles fängt mit der Placenta an: Wie frühe Störungen sich auf spätere Schwangerschaftskomplikationen auswirken.</i>
09/2009	Zertifikat der Fetal Medicine Foundation Certificate of competence in the 11-13 weeks scan
09/2010	Zertifikat der Fetal Medicine Foundation Certificate of competence in the 11-13 weeks scan
09/2011	Zertifikat der Fetal Medicine Foundation Certificate of competence in the 11-13 weeks scan
09/2012	Zertifikat der Fetal Medicine Foundation Certificate of competence in the 11-13 weeks scan
09/2013	Zertifikat der Fetal Medicine Foundation Certificate of competence in the 11-13 weeks scan

HOCHSCHULDIDAKTIK KURSE

05/2005	Modul I
11/2006	Modul II
09/2006	Modul III
09/2006	Modul IV
12/2006	Modul V
05/2004	Wahlmodul I (Problemorientiertes Lernen)
03/2007	Wahlmodul II (Führungspraxis: Orientierungsmodelle)

MANAGEMENT-WEITERBILDUNG

05/2011	Seminar Führung mit Energie und Fokus, Universität St. Gallen
07/2011	Leadership und Management im Universitätsspital Basel

BERUFLICHE AUSBILDUNG

1996-1997	<i>Geriatrische Abteilung, Adullamstiftung Basel</i> Chefarzt: Dr. med. H.-J. Ledermann
1998	<i>Chirurgische Abteilung, Gemeindespital Riehen</i> Chefarzt: Dr. med. P. Nussberger
1999	<i>Gynäkologisch-Geburtshilfliche Klinik, Kantonsspital Bruderholz</i> Chefarzt: Prof. Dr. med. S. Heinzl

- 2000-2004 *Frauenklinik, Universitätsspital Basel*
Chefarzt/Vorsteher:
Prof. Dr. med. Dr. h.c. mult. W. Holzgreve, MS, FRCOG, FACOG
- 01-12/2005 *Tufts-New England Medical Center, Boston*
Chefärztin: Prof. Dr. med. D. Bianchi
- 2006-2008 *Frauenklinik, Universitätsspital Basel*
Chefarzt/Vorsteher:
Prof. Dr. med. Dr. h.c. mult. W. Holzgreve, MS, FRCOG, FACOG
- 11/2008-07/2012 *Frauenklinik, Universitätsspital Basel*
Chefarzt/Vorsteher: Prof. Dr. med. J. Bitzer
- 07/2012- *Frauenklinik, Universitätsspital Basel*
Chefärztin/Vorsteherin: Prof. Dr. med. V. Heinzelmann

STIPENDIEN/UNTERSTÜTZUNG

- 2005 *Personenförderung, Schweizerischer Nationalfonds*
(PBBSB-108590)
Betrag: 47'000 SFr. (35'680 US \$)
Dauer: 12 Monate (1/2005 – 12/2005)
- 2006 *Projektförderung, Schweizerischer Nationalfonds*
Antenatal care and delivery outcome in HIV infected Women in Switzerland. (K. Aebi Popp, O. Lapaire, O. Kaiser, B. Martinez de Tejada, L. Elzi, D.Wunder, G. Drack, I. Hösli and MoCHiV).
Betrag: 6'000 SFr.
Dauer: 6 Monate (1/2007 – 6/2007)
- 2008 *Projektförderung, Freie Akademische Gesellschaft, Basel*
Entwicklung früher nicht-invasive Biomarker und deren Bedeutung für die Diagnose und die Überwachung der Präeklampsie: die Vorhersagekraft von zellfreier fetaler DANN, des angiogenen Faktors (Fms-like tyrosine kinase-1 (sfkt.1), des plazentaren Wachstumsfaktors (PIGF) und von P-Selectin. O. Lapaire, C. Rusterholz, S. Hahn, W. Holzgreve.
Betrag: 11'160 SFr.
Dauer: 12 Monate (12/2008 – 12/2009)

- 2010 *Projektförderung, Schweizerischer Nationalfonds*
Epigenetic placental alterations in preeclampsia 310030_129654
S. Hahn, O. Lاپaire, M. Buehler.
Betrag: 375'000 SFr.
Dauer: 01.04.2010 – 31.03.2013
- 2010 *Projektförderung, Roche Basel*
Sequential automated measurement of the sFlt-1/PIGF ratio in high risk patients for preeclampsia. O. Lاپaire.
Betrag: 130'000 SFr.
Dauer: 10/2010 – heute

LEHRE

- 2002-2004, 2006- *Basler Ultraschall Seminare nach den Richtlinien der SGUM*
(Schweiz. Gesellschaft für Ultraschall in der Medizin)
2-4 Vorträge / Jahr
- 2003-2004 *International School for Ultrasound, Prizren, Kosovo*
2 Tage Fortbildung und Vorträge / Jahr
- 2002-2004, 2006 - *Bildungszentrum Gesundheit Basel-Stadt*
6 Stunden Vorlesung / Semester
- 2002-2004, 2006 - *Universität Basel, Medizinische Fakultät*
Gruppenunterricht 4. Jahreskurs. 5x 120 Minuten / Semester
- 2006- *Universität Basel, Medizinische Fakultät*
Vorlesungen 2., 6. Jahreskurs
- 2006- *SBK Bildungszentrum in Zürich*
3 Stunden Vorlesung / Jahr
- 2006-2010 *Universität Basel, Medizinische Fakultät*
Vorlesungen für das Team Notfallweiterbildung

FACHSPEZIFISCHE MITGLIEDSCHAFT

- 2006- Schweizerische Akademie für feto-maternale Medizin
- 2007- Schweizerische Gesellschaft für Ultraschall in der Medizin, Sektion Geburtshilfe und Gynäkologie
- 2007- Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe

AKTIVITÄTEN IN FACHZEITSCHRIFTEN

2006-2008	Editorial Assistant, <i>Journal of Fetal Diagnosis and Therapy</i>
2009- <i>Therapy,</i>	Member of the Editorial Board, <i>Journal of Fetal Diagnosis and The Journal of Obstetrics and Gynaecology Research</i>
2013-	Member of the Editorial Board, <i>Journal of Disease Markers</i>

AKTIVITÄTEN IN ADVISORY BOARDS

2008-	Roche sFlt and PIGF biomarkers in preeclampsia
2009-	Tibotec Prezista® (Darunavi) and pregnancy
2011	Novartis Diagnostics prenatal advisory board
2014-	Roche sFlt and PIGF biomarkers in preeclampsia

GUTACHTERTÄTIGKEIT

2006-	Regelmässige Gutachtertätigkeit bei geburtshilflichen Fällen für die FMH (Verbindung der schweizerischen Ärztinnen und Ärzte) und Versicherungen
-------	--

US PATIENT ANMELDUNG

08/2006 <i>cell-free</i>	US Natl Patent Application pending: <i>Prenatal diagnosis using fetal DNA in amniotic fluid.</i>
08/2006	US Natl Patent Application pending: <i>Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis.</i>
02/2014 <i>microRNA</i>	European Patent Office: <i>Prediction of Preeclampsia using Patent Case 56135-EP-EPA, S. Lallevee, O. Lapaire, M. Buehler.</i>

PUBLIKATIONEN

1. **Lapaire O**, Schiesser M, Tercanli S, Holzgreve W. Möglichkeiten der intrauterinen Therapie bei Risikograviditäten. Reproduktionsmedizin 2002; 18:269-75
2. **Lapaire O**, Schiesser M, Peukert R, Holzgreve W, Tercanli S. Split hand and foot malformation: ultrasound detection in the first trimester. Ultrasound Obstet Gynecol 2002; 20:511-2
3. **Lapaire O**, Bernhard P, Buser U, Wyss H. Ungewöhnliche Ursache einer chronischen Anämie. Praxis 2002; 91:657-8
4. Schiesser M, Holzgreve W, **Lapaire O**, Willi N, Lüthi H, Lopez R, Tercanli S. Sirenomelia, the mermaid syndrome – detection in the first trimester. Prenat Diagn 2003; 23:493-5
5. **Lapaire O**, Güth U, Holzgreve W, Hösli I. Fetale Pulsoxymetrie: Akzeptanz der Mütter und des geburtshilflichen Teams. Geburtsh Frauenheilk 2003; 63:140-4
6. Schiesser M, **Lapaire O**, Holzgreve W, Tercanli S. Umbilical cord edema associated with patent urachus. Ultrasound Obstet Gynecol 2003; 22:646-7
7. Schiesser M, **Lapaire O**, Tercanli S, Holzgreve W. Lost intrauterine devices during pregnancy: maternal and fetal outcome after ultrasound guided extraction. An analysis of 82 cases. Ultrasound Obstet Gynecol 2004; 23:486-9
8. **Lapaire O**, Rudin C, Güth U, Holzgreve W, Hösli I. Human Immunodeficiency Virus (HIV): Aktuelles aus der Geburtshilfe. Pädiat Prax 2004; 64:603-13
9. Babochkina T, Mergenthaler S, **Lapaire O**, Kiefer V, Yura H, Koike K, Holzgreve W, Hahn S. Evaluation of a Soybean Lectin based method for the enrichment of erythroblasts. J Histochem Cytochem. 2005 Mar;53(3):329-30
10. **Lapaire O**, Sartorius , Holzgreve W, Tercanli S. Aktuelles beim geburtshilflichen Ultraschall: Sonographisches Ersttrimester Screening in der Schweiz. Schweiz Rundsch Med Prax. 2005 Feb 9;94(6):199-204
11. Tschudin S, **Lapaire O**. Antidepressants and pregnancy. Ther Umsch. 2005 Jan;62(1):17-22
12. **Lapaire O**, Zimmermann B, Hahn S, Holzgreve W. Die nichtinvasive Pränataldiagnostik aus dem mütterlichen Blut: Schrittweiser Einzug in den klinischen Alltag. J Reproduktionsmed Endokrinol 2005; 2:272-7
13. **Lapaire O**, Irion O, Holzgreve W, Koch A, Rudin Ch, Hösli and the Swiss Mother and Child HIV Cohort Study–Higher blood loss in HIV-1 infected women after elective cesarean section- a Swiss multicenter study. Arch Gynecol Obstet. 2006, 274(3):165-169
14. Chinnapapgari SK, Holzgreve W, **Lapaire O**, Zimmermann B, Hahn S. Treatment of maternal blood samples with formaldehyde does not lead to the improved recovery of circulatory fetal nucleic acids (DNA and mRNA). Clin Chem. 2005;51(3):652-5
15. Mergenthaler S, Babochkina T, Kiefer V, **Lapaire O**, Holzgreve W, Hahn S. FISH analysis of all fetal nucleated cells in maternal whole blood: improved specificity by the use of two Y-chromosome probes. J Histochem Cytochem. 2005 Mar;53(3):319-22
16. Zanetti-Daellenbach R, **Lapaire O**, Maertens A, Frei R, Holzgreve W, Hosli I. Water birth: is the water an additional reservoir for group B streptococcus? Arch Gynecol Obstet. 2006 Jan;273(4):236-238

17. Chiu RW, Chan CW, Zhong XY, **Lapaire O**, Holzgreve W, Hahn S, Lo YM. Fetal rhesus D mRNA is not detectable in maternal plasma. Clin Chem. 2005 Nov;51(11):2210-1.
18. **Lapaire O**, Stroh H, Peter I, Cowan JM, Tantravahi U, O'Brien B, Bianchi DW, Johnson KL. Larger columns and change of lysis buffer increase the yield of cell-free DNA extracted from amniotic fluid. Clin Chem. 2006 Jan;52(1):156-7
19. Bianchi DW, Wataganara T, **Lapaire O**, Tjoa ML, Maron JL, Larrabee P, Johnson KL. Fetal nucleic acids in maternal body fluids: an update. Ann NY Acad Sci 2006; 1075:63-73
20. **Lapaire O**, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Georg Schmorl on Trophoblasts in the Maternal Circulation. Placenta. 2007; 28(1):1-5
21. Zanetti-Daellenbach R, **Lapaire O**, Maertens A, Holzgreve W, Hosli I. Water birth, more than a trendy alternative: a prospective, observational study. Arch Gynecol Obstet; 2006 Oct;274(6):355-365
22. **Lapaire O**, Schneider MC, Stotz M, Surbek DV, Holzgreve W, Hoesli IM. Oral misoprostol vs. Intravenous oxytocin in reducing blood loss after indicated or elective cesarean delivery. Int J Gynaecol Obstet 2006; 95:2-7
23. **Lapaire O**, Holzgreve W, Zanetti-Daellenbach R, Moffat Ecker R, Hösli IM, Tercanli S. Polyhydramnios: an update. Ultrasound Rev Obstet Gynecol 2006; 1:88-94
24. **Lapaire O**, Bianchi DW, Peter I, O'Brien B, Stroh H, Cowan JM, Tantravahi U, Johnson KL. Cell-Free Fetal DNA in Amniotic Fluid: Unique Fragmentation Signatures in Euploid and Aneuploid Fetuses. Clin Chem 2007;53(3):405-11
25. **Lapaire O**, Zanetti R, Holzgreve W, Hösli I. Intrapartales Monitoring: aktueller Stellenwert der gebräuchlichsten Methoden. Hebamme 2006; 19:170-3
26. **Lapaire O**, Holzgreve W, Miny P, Höli I, Hahn S, Tercanli S. Neue Möglichkeiten in der pränatalen Diagnostik. Ther Umsch 2006; 683-91
27. Hösli I, Holzgreve W, **Lapaire O**. Prävention von Frühgeburten. Gynäkologe 2006; 39:293-6
28. Zanetti-Daellenbach R, Tschudin S, **Lapaire O**, Holzgreve W, Wight E, Bitzer J. Psychological management of pregnancy-related breast cancer. Breast 2006; 15: S57-63
29. **Lapaire O**, Zanetti-Daellenbach R, Weber P, Hösli I, Holzgreve W, Surbek DV. Labor induction in preeclampsia: Is misoprostol more effective than dinoprostone ? J Perinat Med. 2007;35(3):195-9
30. **Lapaire O**, Hösli I, Zanetti-Daellenbach R, Huang D, Jaeggi C, Gatfield-Mergenthaler S, Hahn S, Holzgreve W. Impact of fetal-maternal microchimerism on women's health – a review. J Matern Fetal Neonatal Med 2007;20:1-5
31. Hoesli I, Zanetti-Daellenbach R, Holzgreve W, **Lapaire O**. Role of omega 3-fatty acids and multivitamins in gestation. J Perinat Med. 2007 Feb;35 Suppl 1:S19-24
32. **Lapaire O**, Lu XY, Johnson KL, Jarrah Z, Stroh H, Cowan JM, Tantravahi U, Bianchi DW. Array-CGH analysis of cell-free fetal DNA in 10 mL of amniotic fluid supernatant. Prenat Diagn 2007 Jul;27(7):616-21.
33. **Lapaire O**, Alder J, Peukert R, Holzgreve W, Tercanli S. Two- versus three-dimensional ultrasound in the second and third trimester of pregnancy: Impact on recognition and maternal-fetal bonding -A prospective pilot study. Arch Gynecol Obstet 2007 Apr 25; 2007 Nov;276(5):475-9.

34. Holzgreve W, Hahn S, Zhong XY, **Lapaire O**, Hosli I, Tercanli S, Mindy P. Genetic communication between fetus and mother: short- and long-term consequences. *Am J Obstet Gynecol.* 2007 Apr;196(4):372-81
35. Alder J, Fink N, **Lapaire O**, Urech C, Meyer A, Bitzer J, Hösli I, Holzgreve W. The effect of migration background on obstetric performance in Switzerland. *Eur J Contracept Reprod Health Care* 2007 (in press)
36. **Lapaire O**, Volgmann T, Huang D, Hahn S, Holzgreve W, Xiao Zhong Y. Maternal smoking: effect on circulating cell-free fetal and total DNA levels in maternal plasma from the second trimester. *Obstet Gynecol* 2007;110(6):1358-63
37. Hösli I, Zanetti-Daellenbach R, Holzgreve W, **Lapaire O**. Rauchen in der Schwangerschaft. *Geburtsh Frauenheilk* 2008; 68:141-6
38. Zanetti-Dällenbach RA, Krause EM, **Lapaire O**, Gueth U, Holzgreve W, Wight E. Impact of hormone replacement therapy on the histologic subtype of breast cancer. *Arch Gynecol Obstet.* 2008 Mar 12; [Epub ahead of print]
39. Hösli I, Zanetti-Daellenbach R, Gairing A, Holzgreve W, **Lapaire O**. Selection of appropriate prostaglandin for the induction of labor at term is more predictive for the achievement of delivery within 24 hours than pre-assessed cervical parameters –a prospective, randomized trial. *Geburtsh Frauenheilk* 2008; 68:147-51
40. Peter I, Tighiouart H, **Lapaire O**, Johnson KL, Bianchi DW, Terrin N. Cell-free DNA Fragmentation Patterns in Amniotic Fluid Identify Genetic Abnormalities and Changes due to Storage. *Diagn Mol Pathol.* 2008 Mar 28
41. **Lapaire O**, Johnson KL, Bianchi DW. Method for extraction of high-quantity and -quality cell-free DNA from amniotic fluid. *Methods Mol Biol.* 2008;444:303-9
42. Zanetti-Dällenbach R, Wight E, Fan AX, **Lapaire O**, Hahn S, Holzgreve W, Zhong XY. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. *Anticancer Res.* 2008 Mar-Apr;28(2A):921-5
43. Schneider MC, **Lapaire O**, Hösli I. Pre-eclampsia and eclampsia. *Anaesthesist* 2008;57:619
44. **Lapaire O**, Huhn E, Hartog M, Zanetti-Daellenbach R. Gestational diabetes - practical approach in the clinic. *Ther Umsch.* 2008 Nov;65(11):675-80
45. Poretti A, Anheier T, Zimmermann R, Boltshauser E, Aebi Ch, Antonelli E, Bär W, Bernet V, Bianchetti M, Bittel M, Blumberg A, Bucher HU, Buetti L, Bussmann E, Carrel O, Cattin PO, Corboz A, Diebold P, Dolivo P, Farron F, Gehri M, Giannoni E, Haenggeli CA, Hodel M, Hohlfeld J, Hüppi P, Imahorn P, Irion O, Kind Ch, Kistler W, Knöpfli B, **Lapaire O**, Laubscher B, Leuthardt R, Lips U, Malzacher A, Mayr J, Mc Dougall J, Micheli JL, Mönkhoff M, Neuhaus TJ, Pezzoli V, Reinhard L, Renevey F, Roten H, Rudin Ch, Schlumbom V, Schwöbel M, Sizonenko S, Stocker S, Stüssi Ch, Tabin R, Terrier P, Wildhaber B, Wildhaber J, Wisser J, Wopmann M, Zachariou Z, Zeilinger G, Zemmouri A, Zimmermann U, Zimmermann H, Beeli D. Neural tube defects in Switzerland from 2001 to 2007: are periconceptual folic acid recommendations being followed? *Swiss Med Wkly* 2008;138(41–42):608–613
46. Banzola I, Kaufmann I, **Lapaire O**, Hahn S, Holzgreve W, Rusterholz C. Isolation of serum nucleic acids for fetal DNA analysis: comparison of manual and automated extraction methods. *Prenat Diagn.* 2008;28(13):1227-31
47. Holzgreve W, **Lapaire O**, Zanetti-Dällenbach R, Hösli I, Hartog M. Die regelwidrige Schwangerschaftsdauer. *Frauenheilkunde up2date* 2008 10; 2: 423 - 440

48. **Lapaire O**, Volgmann T, Grill S, Hoesli I, Zanetti-Daellenbach R, Zhong XY, Holzgreve W. Significant Correlation Between Maternal Body Mass Index at Delivery and in the Second Trimester, and Second Trimester Circulating Total Cell-free DNA Levels. *Reprod Sci Reprod Sci* 2009;16(3):274-9
49. Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, **Lapaire O**. *Reprod Biol Endocrinol.* 2009;7:70
50. Ruether KV, Hösli I, Bitzer J, **Lapaire O**. Alltagsrelevante Infektionen von Schwangeren – Diagnostik und Therapie. *Frauenheilkunde up2date* 2009; 4: 273 – 88
51. Sikora A, Zimmermann BG, Rusterholz C, Birri D, Kolla V, **Lapaire O**, Hoesli I, Kiefer V, Jackson L, Hahn S. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. *Clin Chem.* 2010 Jan;56(1):136-8
52. Kolla V, Jenö P, Moes S, Tercanli S, **Lapaire O**, Choolani M, Hahn S. Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). *J Biomed Biotechnol.* 2010;2010:952047
53. Martinez de Tejada B, Martillotti G, **Lapaire O**, Hoesli I, Irion O. The risk of placental abruption when using prostaglandins for cervical ripening in women with preeclampsia: Comparing misoprostol versus dinoprostone. *J Matern Fetal Neonatal Med.* 2009 Nov 27. [Epub ahead of print]
54. Bellido ML, Radpour R, **Lapaire O**, De Bie I, Hösli I, Bitzer J, Hmadcha A, Zhong XY, Holzgreve W. MALDI-TOF mass array analysis of RASSF1A and SERPINB5 methylation patterns in human placenta and plasma. *Biol Reprod.* 2010 Apr;82(4):745-50
55. Aebi-Popp K, **Lapaire O**, Glass TR, Vilén L, Rudin C, Elzi L, Battegay M, Keiser O, Martinez de Tejada B, Hoesli I. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. *J Perinat Med.* 2010 Feb 25. [Epub ahead of print]
56. Bettelheim D, Panzer S, Reesink HW, Csapo B, Pessoa C, Guerra F, Wendel S, Calda P, Sprogøe U, Dziegiel M, Aitokallio-Tallberg A, Koskinen S, Kuosmanen M, Legler TJ, Stein W, Villa S, Villa MA, Trespidi L, Acaia B, Vandenbussche FP, Brand A, de Haas M, Kanhai HH, Gounder D, Flanagan P, Donegan R, Parry E, Sefonte C, Skulstad SM, Hervig T, Flesland O, Zupańska B, Uhrynowska M, **Lapaire O**, Zhong XY, Holzgreve W. Monitoring and treatment of anti-D in pregnancy. *Vox Sang.* 2010 Mar 17. [Epub ahead of print]
57. **Lapaire O**, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. *Eur J Obstet Gynecol Reprod Biol.* 2010 May 8. [Epub ahead of print]
58. Hartog M, **Lapaire O**, Holzgreve W. Rolle der fetomaternalen Transfusion für die Präeklampsie. *Gynäkol Prax* 2010; 34:283-90
59. Wellmann S, Benzing J, Cippà G, Admaty D, Creutzfeldt R, Mieth RA, Beinder E, **Lapaire O**, Morgenthaler NG, Haagen U, Szinnai G, Bühner C, Bucher HU. High copeptin concentrations in umbilical cord blood after vaginal delivery and birth acidosis. *J Clin Endocrinol Metab.* 2010 Nov;95(11):5091-6.
60. Schmid SM, **Lapaire O**, Huang DJ, Jürgens FE, Güth U. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy. *Arch Gynecol Obstet.* 2010 Dec 18. [Epub ahead of print]
61. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, **Lapaire O**, Mandia L, Nicolaidis K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H. Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk

- assessment and model systems to tailor preventive strategies? *Placenta*. 2011 Feb;32 Suppl:S4-16. Epub 2010 Dec 23.
62. Hahn S, Rusterholz C, Hösli I, **Lapaire O**. Cell-free nucleic acids as potential markers for preeclampsia. *Placenta*. 2011 Feb;32 Suppl:S17-20
 63. Kalf K, Hochstrasser L, **Lapaire O**, Hegi L, Benzing J, Hösli I. Severe Neonatal Blood Loss due to Umbilical Cord Rupture in an Underwater Birth. *Z Geburtshilfe Neonatol*. 2011 Feb;215(1):41-44. Epub 2011 Feb 23
 64. Benzing J, Wellmann S, Achini F, Letzner J, Burkhardt T, Beinder E, Morgenthaler NG, Haagen U, Bucher HU, Bühler C, **Lapaire O**, Szinnai G. Plasma Copeptin in Preterm Infants: A Highly Sensitive Marker of Fetal and Neonatal Stress. *J Clin Endocrinol Metab*. 2011 Mar 30. [Epub ahead of print]
 65. Birkenmaier A, Ries JJ, Kuhle J, Bürki N, **Lapaire O**, Hösli I. Placental α -microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies. *Arch Gynecol Obstet*. 2011 Apr 8. [Epub ahead of print]
 66. Visca E, **Lapaire O**, Hoesli I, Hahn S. Cell-free fetal nucleic acids as prenatal biomarkers. *Expert Opin Med Diagn* 2011; 5:151-160
 67. Hahn S, **Lapaire O**, Tercanli S, Kolla V, Hösli I. Determination of fetal chromosome aberrations from fetal DNA in maternal blood: has the challenge finally been met? *Expert Rev Mol Med*. 2011 May 4;13:e16.
 68. Zanetti Dällenbach R, **Lapaire O**. Fertility preservation and pregnancy in gynecological cancers. *Ther Umsch*. 2011 Oct;68(10):573-80. Review. German.
 69. Verlohren S, Herraiz I, **Lapaire O**, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PIGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. *Am J Obstet Gynecol*. 2012 Jan;206(1):58.e1-8. Epub 2011 Jul 30.
 70. Birkenmaier A, Ries JJ, **Lapaire O**, Hösli I. Methods for the diagnosis of rupture of the fetal membranes in equivocal cases. *Eur J Obstet Gynecol Reprod Biol*. 2012 Mar;161(1):115-6;
 71. Admaty D, Benzing J, Burkhardt T, **Lapaire O**, Hegi L, Szinnai G, Morgenthaler NG, Bucher HU, Bühler C, Wellmann S. Plasma midregional proadrenomedullin in newborn infants: impact of prematurity and perinatal infection. *Pediatr Res*. 2012 Mar 23. doi: 10.1038/pr.2012.38. [Epub ahead of print]
 72. **Lapaire O**, Grill S, Lalevee S, Kolla V, Hösli I, Hahn S. Microarray screening for novel preeclampsia biomarker candidates. *Fetal Diagn Ther*. 2012;31(3):147-53. Epub 2012 Mar 29.
 73. Kolla V, Jenö P, Moes S, **Lapaire O**, Hoesli I, Hahn S. Quantitative Proteomic (iTRAQ) Analysis of 1st Trimester Maternal Plasma Samples in Pregnancies at Risk for Preeclampsia. *J Biomed Biotechnol*. 2012;2012:305964. Epub 2012 Apr 10
 74. Kaufmann I, Rusterholz C, Hösli I, Hahn S, **Lapaire O**. Can detection of late-onset PE at triage by sflt-1 or PIGF be improved by the use of additional biomarkers? *Prenat Diagn*. 2012 Dec;32(13):1288-94. doi: 10.1002/pd.3995
 75. De Geyter C, Sterthaus O, Miny P, Wenzel F, **Lapaire O**, De Geyter M, Sartorius G. First successful pregnancy in Switzerland after prospective sex determination of the embryo through the separation of X-chromosome bearing spermatozoa. *Swiss Med Wkly*. 2013 Feb 15;143:0. doi: 10.4414/smw.2013.13718

76. Hahn S, Hösli I, **Lapaire O** Non-invasive prenatal diagnostics using next generation sequencing: technical, legal and social challenges. *Expert Opin Med Diagn.* 2012 Nov;6(6):517-28
77. Verlohren S, Herraiz I, **Lapaire O**, Schlemback D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. *Hypertension.* 2014 Feb;63(2):346-52
78. Manegold-Brauer G, Bellin AK, Tercanli S, **Lapaire O**, Heinzelmann-Schwarz V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. *Arch Gynecol Obstet.* 2014 Mar;289(3):491-8
79. Manegold-Brauer G, Kang Bellin A, Hahn S, De Geyter C, Buechel J, Hoesli I, **Lapaire O**. A new era in prenatal care: non-invasive prenatal testing in Switzerland. *Swiss Med Wkly.* 2014 Feb 4;144:w13915
80. Joerger-Messerli MS, Hoesli IM, Rusterholz C, **Lapaire O**. Stimulation of monocytes by placental microparticles involves toll-like receptors and nuclear factor kappa-light-chain-enhancer of activated B cells. *Front Immunol.* 2014 Apr 15;5:173
81. Manegold-Brauer G, Hahn S, **Lapaire O**. What does next-generation sequencing mean for prenatal diagnosis? *Biomark Med.* 2014 Apr;8(4):499-508
82. Hahn S, Giaglis S, Buser A, Hoesli I, **Lapaire O**, Hasler P. Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists? *J Reprod Immunol.* 2014 Apr 26. pii: S0165-0378(14)00037-0
83. Wellmann S, Benzing J, Fleischlin S, Morgenthaler N, Fouzas S, Bühler CA, Szinnai G, Burkhardt T, **Lapaire O**. Cardiovascular Biomarkers in Preeclampsia at Triage. *Fetal Diagn Ther.* 2014 May 17. [Epub ahead of print]
84. Burckhardt MA, Wellmann M, Fouzas S, **Lapaire O**, Burkhardt T, Benzing J, Bühler C, Szinnai G, Wellmann S. Sexual disparity of copeptin in healthy newborn infants. *J Clin Endocrinol Metab.* 2014 Sep;99(9):E1750-3. doi: 10.1210/jc.2014-2244. Epub 2014 Jul 8.
85. Lalevéé S, **Lapaire O**, Bühler M. miR455 is linked to hypoxia signaling and is deregulated in preeclampsia. *Cell Death Dis.* 2014 Sep 4;5:e1408. doi: 10.1038/cddis.2014.368.
86. Stepan H, Herraiz I, Schlemback D, Verlohren S, Brennecke S, Chantraine F, Klein E, **Lapaire O**, Llurba E, Ramoni A, Vatish M, Wertaschnigg D, Galindo A. Implementation of the sFlt-1/PIGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. *Ultrasound Obstet Gynecol.* 2015 Mar;45(3):241-6. doi: 10.1002/uog.14799. No abstract available.
87. Hahn S, **Lapaire O**, Than NG. Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary? *Expert Rev Mol Diagn.* 2015 Mar 16:1-13. [Epub ahead of print]
88. Burke O, Benton S, Szafranski P, von Dadelszen P, Buhimschi C, Cetin I, Chapell L, Figueras F, Galindo A, Herraiz I, Holzman C, Hubel C, Knudsen U, Kronborg C, Laivuori H, McElrath T, Moertl M, Meyers J, Ness RB, Oliviera L, Olson G, Poston L, Ris-Stalpers C, Roberts JM, Schistermann E, Steegers E, Stepan H, **Lapaire O**, Schlemback D, Timmermans S, Tsatsaris V, van der Post JA, Verlohren S, Villa PM, Williams D, Zeisler H, Zhang C, Redman C, Staff AC; Global Pregnancy CoLaboratory. [94-OR]: Extending the scope of individual patient data meta-analyses: Merging algorithms for biomarker measurements from heterogeneous laboratory platforms. *The*

CoLAB Preeclampsia angiogenic factor study. *Pregnancy Hypertens.* 2015 Jan;5(1):50-1. doi: 10.1016/j.preghy.2014.10.098. Epub 2015 Feb 23.

89. Buechel J, Berset A, Lehmann MA, **Lapaire O**. Unresponsive primipara after rupture of membranes. *BMJ Case Rep.* 2015 Apr 16;2015. pii: bcr2015209765. doi: 10.1136/bcr-2015-209765.

BUCHBEITRÄGE:

1. **Lapaire O**, Hösli I, Holzgreve W. Spezielle klinische Pharmakologie in der Schwangerschaft. In: *Klinische Pharmakologie.* (Eds. Kuemmerle HP, Hitzenger G, Spitzky KH), ecomed Fachverlag, 4. Auflage, Erg. Lfg 9/2002
2. **Lapaire O**, Hösli I, Holzgreve W. Pharmakotherapie des Wochenbetts. In: *Klinische Pharmakologie.* (Eds. Kuemmerle HP, Hitzenger G, Spitzky KH), ecomed Fachverlag, 4. Auflage, Erg. Lfg 9/ 2002
3. **Lapaire O**, Zimmermann B, Zhong XY, Hahn S, Holzgreve W. Non-invasive prenatal diagnosis of the maternal blood:-further improvements for the clinical everyday life. *Textbook of perinatal medicine*, (Eds: A. Kurjak and FA Chervenak), 2nd edition, informa healthcare 2006
4. Holzgreve W, Zanetti-Dällenbach R, De Geyter C, Miny P, Tercanli S, **Lapaire O**, Hösli I, Hahn S. Fetal cells in the maternal blood: Diagnostic and clinical aspects. *Textbook of perinatal medicine*, (Eds: A. Kurjak and FA Chervenak), 2nd edition, informa healthcare 2006
5. Zanetti-Daellenbach R., Hösli I, Holzgreve W, **Lapaire O**. Pharmakotherapie des Wochenbetts. In: *Klinische Pharmakologie.* (Eds. Kuemmerle HP, Hitzenger G, Spitzky KH), ecomed Fachverlag, 6. Auflage, Erg. Lfg 10/ 2006
6. **Lapaire O**, Johnson KL, Bianchi DW. Method for the extraction of high quantity and quality cell-free DNA from amniotic fluid. *Methods in Molecular Biology Book Series Format Guide*, TheHumanPress Inc 2007 (in Press)
7. **Lapaire O**, Zanetti-Daellenbach R., Holzgreve W, Hösli I. Spezielle klinische Pharmakologie in der Schwangerschaft. In: *Klinische Pharmakologie.* (Eds. Kuemmerle HP, Hitzenger G, Spitzky KH), ecomed Fachverlag, 6. Auflage, Erg. Lfg 12/ 2006
8. Egone (E-learning Gynecology, Obstetrics, Neonatology, Endocrinology): Frühgeburt und Uebetragung. Zanetti-Dällenbach R, **Lapaire O**, Hösli I, Holzgreve W. www.olat.unizh.ch
9. Zanetti-Dällenbach R, Holzgreve W, Hahn S, Hösli I, Herberich L, **Lapaire O**. Diagnostico prenatal no invasivo en sangre maternal: Implementacion clinica gradual. *Libro de Obstetricia y Medicina Materno-Fetal* (Cabero L, Saldivar D, Cabrillo E, editors). Editorial Medica Panamericana, 2007, chapter 165, p.1305-8
10. Visca E, **Lapaire O**, Holzgreve W. *Lehrbuch Allgemeine und viszerale Chirurgie des Kindesalters Kapitel 10. Pränatale Diagnostik und Interventionen* (v. Schweinitz D, editor [in Press])
11. **Olav Lapaire**, Sinuhe Hahn, Wolfgang Holzgreve. Non-invasive screening and diagnosis from maternal blood. In: *Fetal Medicine* (Rodeck CH, Whittle MJ, editors), second edition, Elsevier, London, p. 282-291, 2009
12. Frühgeburt und Uebetragung. Visca E, Zanetti Dällenbach , **Lapaire O**, Hösli I. (E-learning Gynecology, Obstetrics, Neonatology, Endocrinology) 2010. www.olat.unizh.ch.

13. Carolyn Troeger, **Olav Lapaire**, XiaoYan Zhong, and Wolfgang Holzgreve. Implications of Feto-maternal Cell Transfer in Normal Pregnancy. Bhattacharya, Niranjana; Stubblefield, Phillip (Eds.), 1st Edition 2011, Springer Verlag
14. **Olav Lapaire**, Wolfgang Holzgreve. Fetal DNA, RNA and prenatal Diagnosis. Placenta: From Development to Disease. Helen Kay, MD (Editor), D. Michael Nelson, MD (Editor), Yuping Wang, MD (Editor), Wiley-Blackwell, first edition, 2011